Clostridioides Difficile Infection (CDI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Clostridioides difficile infection (CDI) is caused by an anaerobic, spore-forming, gram-positive bacterium that resides in the intestinal tract of individuals, particularly those whose normal gut microbiota has been disrupted due to antibiotic therapy or other factors. C. difficile bacterium produces two primary toxins, A and B, which damage the intestinal mucosa, leading to symptoms such as diarrhea and colitis. In severe cases, the infection can progress to shock, ileus, and toxic megacolon. In high-income countries, C. difficile infection is the leading cause of infectious diarrhea among hospitalized patients. Initial antibiotic treatment fails in 20% to 35% of cases; 40% to 60% experience a second recurrence among these individuals. The recurrence of C. difficile infection after the initial treatment imposes significant morbidity and burdens healthcare systems substantially. The FDA has approved several drugs to treat C. difficile infections, including Fidaxomicin (Dificid), Vowst, Rebyota, and Fecal microbiota transplantation (FMT). Recurrent infections affect approximately 15% to 35% of CDI patients, often representing a relapse of the same infection rather than a new strain causing reinfection. Second and subsequent recurrences are even more common following the first recurrence. In the United States alone, C. difficile infection is responsible for about half a million illnesses yearly.

·       It is recognized as one of the most prevalent hospital-acquired infections, and one in 11 individuals over 65 succumbs to healthcare-associated C. difficile infection.

 

Thelansis’s “Clostridioides Difficile Infection (CDI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Clostridioides Difficile Infection (CDI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Clostridioides Difficile Infection (CDI) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Clostridioides Difficile Infection (CDI) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Clostridioides Difficile Infection (CDI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Clostridioides Difficile Infection (CDI), Clostridioides Difficile Infection (CDI) market outlook, Clostridioides Difficile Infection (CDI) competitive landscape, Clostridioides Difficile Infection (CDI) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

 

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more